Health Care & Hospital Law
Dec. 23, 2010
Pharmaceutical Marketing: A Year of Interesting Times
New disclosure rules target conflicts of interests between drug providers and the industry. By Bryan A. Liang and Tim K. Mackey of the California Western School of Law.
2010 was a busy year in pharmaceutical marketing. With pipelines dwindling, drug makers continue to concentrate on marketing to drive product sales. However, increasing regulatory scrutiny over the past year is reshaping the landscape of pharmaceutical promotion.
Headlining pharmaceutical marketing reform was the passage of physician payment disclosure provisions under the Affordable Care Act. Starting Jan. 1, 2012, ...
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$895, but save $100 when you subscribe today… Just $795 for the first year!
Or access this article for $45
(Purchase provides 7-day access to this article. Printing, posting or downloading is not allowed.)
Already a subscriber?
Sign In